Markus Dietlein
Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
van Heek L, Stuka C, Kaul H, Müller H, Mettler J, Hitz F, Baues C, Fuchs M, Borchmann P, Engert A, Dietlein M, Voltin C, Kobe C. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial. BMC cancer 2022; 22:672.
18.06.2022Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma - Data from the prospective, multicenter phase III HD16 trial.
18.06.2022BMC cancer 2022; 22:672
van Heek Lutz, Stuka Colin, Kaul Helen, Müller Horst, Mettler Jasmin, Hitz Felicitas, Baues Christian, Fuchs Michael, Borchmann Peter, Engert Andreas, Dietlein Markus, Voltin Conrad-Amadeus, Kobe Carsten
PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
Kreissl S, Keller U, Kühnhardt D, Ostermann H, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Dietlein M, Engert A, Borchmann P, Bentz M, Hitz F, Topp M, Goergen H, Buehnen I, Kobe C, Moccia A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, German Hodgkin Study Group. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol 2021; 8:e398-e409.
01.06.2021PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial
01.06.2021Lancet Haematol 2021; 8:e398-e409
Kreissl Stefanie, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Diehl Volker, Dietlein Markus, Engert Andreas, Borchmann Peter, Bentz Martin, Hitz Felicitas, Topp Max S, Goergen Helen, Buehnen Ina, Kobe Carsten, Moccia Alden, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, German Hodgkin Study Group
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
Borchmann P, Bentz M, Keller U, Kühnhardt D, Ostermann H, Schmitz N, Hertenstein B, Aulitzky W, Maschmeyer G, Vieler T, Eich H, Baues C, Stein H, Fuchs M, Kuhnert G, Diehl V, Dietlein M, Hitz F, Topp M, Goergen H, Kobe C, Lohri A, Greil R, Eichenauer D, Zijlstra J, Markova J, Meissner J, Feuring-Buske M, Hüttmann A, Dierlamm J, Soekler M, Beck H, Willenbacher W, Ludwig W, Pabst T, Engert A. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet 2017; 390:2790-2802.
20.10.2017PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group
20.10.2017Lancet 2017; 390:2790-2802
Borchmann Peter, Bentz Martin, Keller Ulrich Bernd, Kühnhardt Dagmar, Ostermann Helmut, Schmitz Norbert, Hertenstein Bernd, Aulitzky Walter, Maschmeyer Georg, Vieler Tom, Eich Hans, Baues Christian, Stein Harald, Fuchs Michael, Kuhnert Georg, Diehl Volker, Dietlein Markus, Hitz Felicitas, Topp Max S, Goergen Helen, Kobe Carsten, Lohri Andreas, Greil Richard, Eichenauer Dennis A, Zijlstra Josée M, Markova Jana, Meissner Julia, Feuring-Buske Michaela, Hüttmann Andreas, Dierlamm Judith, Soekler Martin, Beck Hans-Joachim, Willenbacher Wolfgang, Ludwig Wolf-Dieter, Pabst Thomas, Engert Andreas